



argenx

Innovative Access Program (IAP)

The power of our unique technology platform

Establishing close collaboration with academic research groups

Unlocking novel targets & elucidating target biology

Creating first-in-class antibodies with product potential




From Innovative Target to Therapeutic Antibody Candidate

IAP Focus Areas

Oncology – Immuno/Oncology + Severe autoimmune diseases

Antibody engine: SIMPLE Antibody™ platform



High potential for future value creation

What's in it for you?



Validate innovative target

- argenx custom designs a SIMPLE Antibody™ selection and screening plan



Diverse antibody set

- argenx performs in-depth characterization of SIMPLE Antibodies in functional assays



Win-win collaboration

- SIMPLE Antibodies made available to explore target biology



PoC in disease model

- Rapid progression into disease relevant animal models



Scientific publication + Patent

- Raise the profile of commercial potential of novel target




Development candidate + back-up

- Antibodies may be taken forward to clinic by argenx under pre-agreed mutually beneficial terms

Success story example

“Combining our expertise in cancer immunology with argenx’s proprietary SIMPLE Antibody™ platform led to the discovery of ARGX-115, the first antibody to show inhibitory activity on the immunosuppressive function of human Tregs. The IAP collaboration brings in the know-how of argenx to validate the GARP protein as a target for cancer immunotherapy.”

Prof. Sophie Lucas, de Duve Institute/UCL/WELBIO



WANT TO DISCUSS COLLABORATION OPPORTUNITIES? CONTACT US.

iap@argenx.com

www.argenx.com